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 1	  
BoneKey Reports - Commentary on  2	  
• Kusumbe AP, Ramasamy SK, Adams RH. Coupling of angiogenesis and 3	  
osteogenesis by a specific vessel subtype in bone. Nature. 2014 Mar 20; 507(7492): 4	  
323-8. (1) 5	  
• Ramasamy SK, Kusumbe AP, Wang L, Adams RH. Endothelial Notch activity 6	  
promotes angiogenesis and osteogenesis in bone. Nature. 2014 Mar 20; 507(7492): 7	  
376-80. (2) 8	  
 9	  
It is a well-established principle that the presence of an adequate vascular supply is 10	  
absolutely required for bone formation. A close spatial-temporal association exists between 11	  
the processes of angiogenesis and osteogenesis during skeletal development in 12	  
embryogenesis, in postnatal growing bones, and during the healing of bone fractures (3). 13	  
Bone homeostasis in the adult also involves a close physical relationship between blood 14	  
vessels and osteoblasts at remodeling sites (4, 5). Moreover, reduced blood flow has been 15	  
linked to old age and low bone mass disorders such as osteoporosis and to impaired 16	  
fracture healing, rendering angiogenic modulation an angle of considerable interest from 17	  
osteo-anabolic therapeutic viewpoints (4, 6). 18	  
 19	  
The intimate relationship between blood vessels and bone formation has been referred to as 20	  
‘angiogenic-osteogenic coupling’ (7-9). Blood vessels near bone formation sites ensure an 21	  
adequate supply of oxygen and nutrients during the energy expensive process of 22	  
ossification, and may also deliver osteo-regulatory factors to their target cells. More recent 23	  
evidence suggests that blood vessels may even play a role in determining the site of bone 24	  
	   3	  
formation, by carrying osteoprogenitors or mesenchymal stem cells with osteoblastic 1	  
differentiation potential in close association with the endothelial wall of skeletal blood 2	  
vessels (see Figure 1) (10-12).  3	  
Conversely, the osteo-chondrocytic cellular compartments of the bones are known to 4	  
determine the growth and integrity of the vascular bed. Studies using genetically altered 5	  
mice and modulatory compounds have provided compelling evidence that the angiogenic 6	  
growth factor VEGF is critical in driving angiogenesis in developing, growing and healing 7	  
long bones (13-18). However, paracrine VEGF-driven effects on angiogenesis represent 8	  
only one aspect of the complex interplay between the chondrocyte and osteoblast lineage 9	  
cells and the vascular supply – and hence the oxygen supply – to these cells. Indeed, the 10	  
cellular oxygen sensing machinery plays crucial roles in chondrocytes, osteoprogenitors 11	  
and osteoblasts, both by regulating their proliferation, differentiation and/or survival cell-12	  
autonomously, and by controlling their production of VEGF that itself can also affect these 13	  
processes by acting in auto-, intra- and paracrine ways (7, 19-23) (Figure 1). The key 14	  
players in coupling the sensing of a relative hypoxic state to cellular responses attempting 15	  
to cope with this state or to remediate it, are the transcription factor hypoxia-inducible 16	  
factor (HIF) and its upstream regulatory components, particularly the prolyl 4-17	  
hydroxylases (PHDs) and the Von Hippel-Lindau (VHL) protein (24). Both of these 18	  
components represent negative regulators of HIF: when sufficient oxygen is available, and 19	  
the hypoxia-adaptive actions of the HIF are consequently unnecessary, the PHD enzymes 20	  
mediate the oxygen-dependent hydroxylation of residues in the α subunit of the HIF1 21	  
protein, rendering it a target for the E3 ubiquitin ligase VHL and subsequent proteasomal 22	  
degradation. In hypoxic conditions – or in experimental, pathological or pharmacological 23	  
circumstances of PHD or VHL inhibition – the HIF-1α protein is stabilized and can 24	  
	   4	  
execute its comprehensive transcriptional program. This includes the activation of genes 1	  
and pathways involved in angiogenesis, erythropoiesis, and cellular metabolism, for 2	  
instance stimulating oxygen-sparing glycolysis (24). Mice with osteoblast-specific deletion 3	  
of VHL developed extremely dense, heavily vascularized long bones, associated with 4	  
expression of high levels of VEGF (19). Conversely, inactivation of HIF-1α in mature 5	  
osteoblasts led to reductions in the bone and blood vessel volume (19). Thus, ample 6	  
previous studies identified VEGF and hypoxia signaling components as key molecular 7	  
players of angiogenic-osteogenic coupling, as viewed from the osteogenic perspective (7, 8	  
8, 20) (Figure 1, upper and right side of the scheme depicting previously published 9	  
findings in brown).  10	  
 11	  
New work by the group of Ralf Adams, recently published as a Letter and an Article in 12	  
Nature (1, 2), for the first time studied signaling in vivo in the endothelial cell (EC) 13	  
compartment of the skeleton directly, by generating EC-specific conditional knockout 14	  
(cKO) mice (Figure 1). The potential problems of embryonic lethality or adverse systemic 15	  
effects that could be associated with the induction of a generalized mutation in the vascular 16	  
system throughout the body were circumvented in this work by using the tamoxifen-17	  
inducible Cre-ERt system in postnatal life. Specifically, a variety of iEC-cKO mice were 18	  
generated by crossing mice carrying floxed alleles of the target genes with the Cdh5(PAC)-19	  
CreERT2 driver to mediate EC-specific recombination following tamoxifen 20	  
administration.  21	  
 22	  
In their article, the authors have analyzed the microarchitecture and properties of the 23	  
bone’s vascular system, using advanced fluorescent staining techniques to visualize EC 24	  
	   5	  
markers in thick sections of murine long bones, and FACS sorting of specific cell 1	  
populations followed by molecular characterization of their transcriptome (1). Based on 2	  
these results, they propose that the vasculature of long bones can be seen as a continuum of 3	  
two subtypes of interconnected blood vessels that have distinct morphological, molecular, 4	  
and functional properties. They term these H-type and L-type vessels, based on the 5	  
expression levels of CD31 (PECAM-1) and Endomucin (Emcn) in the ECs that make up 6	  
their walls. CD31high/Emcnhigh cells (defining ‘H-type vessels’) typify the blood vessels at 7	  
the endosteal surfaces and those in the metaphysis, which run as longitudinal tubes towards 8	  
the chondro-osseous junction of the growth plate, where they form arch-shaped vessel 9	  
loops as their distal ends reach the terminal row of hypertrophic chondrocytes. In contrast, 10	  
the lining of the sinusoidal capillaries deeper in the diaphysis consists of CD31low/Emcnlow 11	  
cells (constituting the ‘L-type vessels’ of the bone marrow vasculature).  12	  
Interestingly, although the CD31high/Emcnhigh ECs represent only a small fraction of the 13	  
total endothelium in a long bone, particularly the H-type microvessels appear to be driving 14	  
vascular growth in bone and express distinct sets of molecules including several growth 15	  
factors that upon secretion (as so-called ‘angiocrine signals’) could modulate osteoblast 16	  
lineage cells. Moreover, perivascular osteoprogenitors, including those expressing Osterix 17	  
(Osx+), were found to selectively associate with type H endothelium in the metaphysis and 18	  
endosteum, and not found around diaphyseal type L vessels (Figure 1). In long bones of 19	  
ageing mice, concomitant with the age-related loss of bone mass, both the type H vessels 20	  
and the abundance of the osteoprogenitor populations drastically reduced (1).  21	  
Functional differences between H- and L-type vessels may affect also the oxygenic and 22	  
metabolic microenvironment they generate. For instance, hypoxia detection was strongest 23	  
in the diaphysis while it was low in the metaphysis, and the presence of the HIF-1α protein 24	  
	   6	  
and some of its transcriptional targets followed this pattern. Yet, ECs of the 1	  
CD31high/Emcnhigh signature expressed higher levels of HIF-1α than CD31low/Emcnlow 2	  
cells, and H-type vessels were more sensitive of loss of HIF-1α than did L-type vessels. 3	  
Indeed, when Kusumbe et al. inactivated HIF-1α in the Cdh5(PAC)-CreERT2+ 4	  
endothelium, a phenotype of severely reduced metaphyseal and endosteal type H 5	  
vascularization resulted in the HIF-1α iEC-cKO mice, whereas the diaphyseal type L 6	  
vessels were maintained. The vascular defects were associated with reduced prevalence of 7	  
perivascular osteoprogenitors. The opposite was seen when the negative regulator of HIF 8	  
signaling VHL was inactivated using the same targeting strategy: these mice had expanded 9	  
metaphyseal vascularization, increased Runx2+ and Osx+ osteoprogenitors, enhanced bone 10	  
formation, and a higher trabecular bone volume (1). 11	  
 12	  
Thus, these data underscore the prime role of the hypoxia-signaling pathway in 13	  
angiogenic-osteogenic coupling, acting both in the endothelial and in the osteogenic 14	  
compartments. The precise mechanisms that mediate the coupling remain to be 15	  
determined, but the fact that the phenotypic outcome of the genetic mutations in the 16	  
VHL/HIF axis in either ECs or OBs appears to be strikingly similar may argue in favor of 17	  
common (secreted) signals driving the crosstalk between the two cell lineages. Although 18	  
not further explored in the current work, VEGF could be a coupling factor. Altering its 19	  
expression in ECs in the current studies (by targeting HIF) might have jeopardized the 20	  
beneficial effects of its autocrine actions in the ECs proper (25), thereby resulting in 21	  
reduced secretion of other angiocrine, osteogenic factors from the endothelium. This could 22	  
perhaps explain the reduced numbers of osteoprogenitors observed in the HIF-1α iEC-23	  
cKO model. Altered levels of EC-derived VEGF secreted in the bone microenvironment 24	  
	   7	  
(speculatively increased in the VHL- and decreased in the HIF-1α iEC-cKO models) could 1	  
also have contributed directly to the changes in ossification due to its paracrine stimulatory 2	  
effects on osteoblast lineage cells. VEGF is known to regulate the migration, proliferation, 3	  
and differentiation of osteogenic cells (reviewed in (12)) and its temporary over-expression 4	  
in postnatal long bones has previously been shown to result in a dramatic phenotype of 5	  
aberrant angiogenesis and osteogenesis, bone marrow fibrosis and hematopoietic 6	  
alterations (15).  7	  
It is important to recognize though that the VHL/HIF pathway regulates several other 8	  
targets, including cellular metabolic pathways, which might have been altered in the mouse 9	  
models studied here. It would be of interest to learn more about the potential contribution 10	  
of this aspect in the observed phenotypes. In addition, the potential role of Noggin in this 11	  
model (see below) also needs further consideration. Another aspect that remains to be 12	  
clarified is how to reconcile the seemingly contradictory aspect on the location of hypoxia 13	  
(particularly in the L-type vascularized regions) and the expression and requirement of HIF 14	  
selectively in the H-type endothelium. 15	  
In any case, the discovery of the role of endothelial VHL/HIF signaling in mediating 16	  
angiogenic-osteogenic coupling is likely to boost therapeutic exploration of this pathway in 17	  
low bone mass disorders such as osteoporosis. As already shown by Kusumbe et al. in this 18	  
paper, the age-related decline in type H capillaries and associated Osx+ osteoprogenitors 19	  
could be reversed by pharmacological treatment of aged mice with the PHD inhibitor 20	  
deferoxamine mesylate (DFM), resulting in a restoration of the bone mass (1). 21	  
 22	  
In the second paper of the Adams group, Ramasamy et al. report on the use of the same 23	  
recombination strategy to analyze the role of Notch signaling in the endothelium of bone 24	  
	   8	  
(2). In the vascular system of most other organs, with the exception of the liver, the Notch 1	  
signaling pathway is a major determinant of the process of vascular expansion through 2	  
sprouting angiogenesis. In brief, an endothelial cell at the forefront of the vessel sprout is 3	  
induced to extend abundant filopodia and lead the growth of the sprout towards the 4	  
angiogenic stimulus, typically a high concentration of VEGF such as emitted from an 5	  
hypoxic region. High VEGF levels induce migration and proliferation in these endothelial 6	  
cells, and strong expression of the Notch ligand Delta‑like ligand 4 (Dll4). Via cell–cell 7	  
contact-dependent signaling between endothelial cells, Dll4 activates Notch in the 8	  
neighboring endothelial cells, which results in blunting of the cell’s responsiveness to 9	  
VEGF signaling (by down-regulating VEGFR2 (Flk-1/KDR) and up-regulating the decoy 10	  
receptor soluble VEGFR1 (sFlt-1)), limitation of sprouting and mitosis, and quiescence of 11	  
the cells that make up the lumen of the growing vasculature (26). Thus, in general, Notch 12	  
negatively regulates angiogenesis. 13	  
Interestingly, analysis of long bones from Notch loss-of-function and gain-of-function 14	  
iEC-cKO mice provides evidence that the mechanism through which Notch controls 15	  
vascular growth in bone differs from this classic sprouting angiogenesis model active in 16	  
other tissues and in tumors (2). Indeed, induction of EC-specific loss of Notch and Dll4 17	  
signaling in 2-week-old mice resulted, by 4 weeks of age, in a drastically reduced number 18	  
of blood vessels that should be growing towards the growth plate in the metaphysis, and 19	  
reduced EC proliferation in these (H-type) vessels. The defective vascularization was 20	  
associated with impaired bone lengthening, severely disorganized growth plates 21	  
characterized by an enlargement of the zone of hypertrophic chondrocytes that however 22	  
virtually lacked Sox9 and VEGF expression, and reduced bone formation and trabecular 23	  
bone volume. While both the number of early osteoblast precursors (Runx2+ cells) and the 24	  
	   9	  
expression levels of mature osteoblast markers were profoundly reduced, the abundance of 1	  
Osx+ osteoprogenitors in the metaphysis was increased. The opposite phenotype was 2	  
observed in the gain of function mutants, which showed increased numbers of vessel 3	  
arches running longitudinally towards the growth plate. Interestingly, Notch signaling in 4	  
the endothelium of bone led to up-regulation of VEGFR2 and down-regulation of sFlt-1, 5	  
precisely opposite to the normal consequences of endothelial Notch/Dll4 signaling. 6	  
Together, these data make a convincing case that Notch signaling in the ECs of postnatal 7	  
long bones promotes endothelial cell proliferation and vessel growth, and couple the 8	  
vascular effects to effects on the growth plate chondrocytes and osteoblast lineage cells, 9	  
affecting bone growth and ossification (2). 10	  
To identify potential downstream mediators of the coupling event, the authors surveyed a 11	  
number of candidate growth factors, including TGF-β, BMPs, FGFs, and Wnts, in bone-12	  
derived ECs sorted from mice carrying a Notch gain-of-function mutation. The expression 13	  
of the secreted BMP antagonist Noggin was most pronouncedly affected, being up-14	  
regulated upon gain-of-function and down-regulated upon loss-of-function of endothelial 15	  
Notch signaling. This finding led the authors to test whether the administration of 16	  
recombinant Noggin could rescue the phenotype of the iEC-cKO Notch pathway mutants. 17	  
Notably, this treatment resulted in a normalization of the bone formation rate, the presence 18	  
of the Osx+ osteoprogenitors in the vascular wall and the organization of the growth plate, 19	  
and even corrected the vascular phenotype itself. Thus, Notch signaling in ECs of bone 20	  
mediates the angiocrine release of Noggin into the bone environment, coupling 21	  
modulations in the vascular system to the functioning of osteoprogenitors, osteoblasts, and 22	  
chondrocytes (2) (Figure 1). 23	  
 24	  
	   10	  
An important conceptual advance stemming from these papers is the notion that 1	  
metaphyseal type H blood vessels may have a unique molecular signature. The vessels 2	  
approaching the growth plate are described morphologically as endothelial columns, 3	  
interconnected by arch-shaped vessel loops at their distal end, which extend budding, 4	  
blind-ended, lumen-containing endothelial protrusions and filopodia towards the 5	  
chondrocytes during active growth (1, 2), corresponding to earlier observations made by 6	  
vascular perfusion methods, corrosion casting, electron microscopy and histology (27, 28). 7	  
Interestingly, this description correlates very closely with that of vessels invading the 8	  
cartilage of the fetal bone template during skeletal development and of the callus tissue 9	  
during fracture healing (10). These neo-angiogenesis processes mediate the conversion of 10	  
the avascular cartilaginous template into actual bone and bone marrow tissue, much like 11	  
the process occurring at the growth plate. It will be interesting to clarify whether these 12	  
vessels fit the type H definition and whether the mechanism of vascular growth in fetal life 13	  
and during bone regeneration corresponds to the unique Notch-stimulated mode of 14	  
angiogenic growth described here to mediate postnatal skeletal growth. We do know that 15	  
in all these settings, VEGF is a prime driver of the angiogenic process (13-18); it is now to 16	  
be determined in follow-up studies how VEGF functions upstream of Notch signaling in 17	  
the bone ECs – according to the classical mechanism operating in ECs of other tissues, 18	  
VEGF would be expected to induce Dll4 and Notch signaling. 19	  
 20	  
In conclusion, the studies published by the Adams team (1, 2) for the first time start to shed 21	  
light on the molecular specialization and functional organization of the peculiar bone 22	  
endothelium, on the intracellular signaling cascades regulating the angiogenic processes 23	  
that are crucial to drive long bone growth and homeostasis, and on the EC-secreted 24	  
	   11	  
angiocrine factors that communicate essential signals to chondrocytes, perivascular 1	  
osteoprogenitors, and osteoblasts in vivo. These new insights into the angiogenic-2	  
osteogenic coupling paradigm will help ongoing and future research aimed at answering 3	  
emerging questions such as whether these mechanisms act universally in settings of bone 4	  
formation, which roles are played by the H-type and the L-type vessels in supporting 5	  
hematopoiesis and in providing entry sites and niches for metastasizing tumor cells homing 6	  
to bone, and if these findings can be effectively translated to angio-osteo-anabolic 7	  
therapeutic applications to battle osteoporosis and promote bone repair and regeneration.  8	  
 9	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Figure 1. Angiogenic-osteogenic coupling mediated by bidirectional cross-talk between 
chondro-/osteoblast lineage cells and skeletal endothelial cells.  
Schematic view of the dynamic and reciprocal interplay between the different cell types in the 
bone environment that couples angiogenesis and osteogenesis. [Right and upper part] 
Previous work implicated the VHL-HIF-VEGF signaling pathway in the osteogenic 
compartment of the long bones as a key driver of angiogenic-osteogenic coupling, by 
effecting both (i) cell-autonomous roles in chondrocytes, osteoprogenitors, and osteoblasts, 
and (ii) VEGF-mediated paracrine effects on the blood vessels in the bone environment, 
stimulating angiogenesis (brown arrows and notifications). [Left and lower part] New work 
from the group of Ralf Adams (red in the scheme) identifies a specialized subtype of 
endothelial cells (ECs), constituting type H vessels in the metaphysis and endosteum. These 
ECs mediate the growth of the blood vessels in bone, through a tissue-selective mechanism of 
angiogenesis involving positive regulation by the VHL/HIF and Notch/Dll4 signaling 
pathways. Coupling of angiogenesis back to osteogenesis is mediated by osteo-regulatory 
signals produced by ECs, i.e. angiocrine, osteogenic signaling. Among the angiocrine signals 
released from H-type vessels, Noggin stood out as the candidate most influential in mediating 
the osteogenic effects; addition of recombinant Noggin rescued the abundance of perivascular 
osteoprogenitors, the growth plate abnormalities and the ossification defect in mice carrying 
EC-specific loss-of-function mutations in the Notch pathway.  
